Invest in MJ Blog

Invest In MJ is a multi-author and community member blog. Read the latest blogs about investment ideas in the marijuana and cannabis industry.

  • Home
    Home This is where you can find all the blog posts throughout the site.
  • Categories
    Categories Displays a list of categories from this blog.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Bloggers
    Bloggers Search for your favorite blogger from this site.
  • Team Blogs
    Team Blogs Find your favorite team blogs here.
  • Archives
    Archives Contains a list of blog posts that were created previously.
  • Login
    Login Login form
Emblem To Disrupt $60 Billion Opiod Market With Cannabis Based Sustained Release Formulation

Emblem Announces Exclusive Agreement with Canntab Therapeutics for Cannabinoid Based Oral Sustained Release Formulation

View Emblem company info and stock price on the directory listing on InvestinMJ.com

PARIS, Ontario, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV:EMC) (EMC.WT) (“Emblem” or the "Company") announced today that it has entered into a Collaboration and Licensing Agreement (the “Agreement”) with Canntab Therapeutics Limited (“Canntab”) of Toronto. Canntab has developed a patent-pending oral sustained release formulation for cannabinoids (the “Sustained Release Product” or the “Product”). Under the Agreement, Emblem and Canntab will collaborate on the preclinical formulation, clinical development, regulatory approval, manufacturing and commercialization of the Sustained Release Product.

The Agreement grants to Emblem the exclusive right in Canada to Canntab’s patents and know-how for the purpose of developing, commercializing, using, selling, and offering the Sustained Release Product for sale under the Emblem brand. The License does not include the right to import or export the Product.

The Sustained Release Product will be manufactured by Emblem or by Canntab, after Canntab receives appropriate licensing allowing such manufacture.

The Agreement calls for Emblem to make payments to Canntab upon achievement of certain milestones involving stability studies, bio-availability studies and regulatory approval of the Sustained Release Product. The Agreement also calls for Emblem to make royalty payments to Canntab based upon Gross Sales of the Product.

Emblem and Canntab also intend to collaborate on the preclinical formulation, clinical development, regulatory approval and commercialization of a range of additional cannabinoid containing pharmaceutical formulations.

Background

There is substantial evidence that cannabinoids are effective for the treatment of a number of conditions including (i) chronic pain (ii) nausea, (iii) anxiety and sleep disorders, and (iv) spasticity in patients with Multiple Sclerosis.

Most conventional (immediate release) dosage forms, such as tablets and capsules, release the active drug component immediately after oral administration. In the formulation of conventional drug products, no deliberate effort is made to modify the drug release rate. Sustained release dosage forms are designed to release the active pharmaceutical ingredient at a predetermined rate in order to maintain a constant drug concentration over a specific period of time – resulting in a longer duration of action from a single dose and often with reduced side effects. Generally this is done to achieve an improved therapeutic outcome and/or to enhance patient compliance. Immediate release dosage forms of cannabinoids tend to lose therapeutic effects in 4 to 6 hours requiring subsequent re-administration and the risk of reduced patient compliance.

The Sustained Release Product is designed to release the cannabinoid content over a period of at least 12 hours. Sustained release formulations of pharmaceutical products are particularly valuable in the treatment of chronic conditions, such as chronic pain, where patients tend to need “around the clock” relief. There is substantial evidence that cannabis is effective for the treatment of numerous conditions including neuropathic pain. Neuropathic pain is estimated to affect over two million Canadians and the pharmaceutical market addressing the needs of those patients was about $500 million in 2016.

John H Stewart – Head of Emblem’s Pharmaceutical Division said: “There are numerous examples of drug products where the utilization of advanced dosage forms such as sustained and/or modified release dosage forms significantly improved the efficacy and clinical utility of the active drug substance. We believe that cannabinoid therapy will be advanced via the development of such dosage forms and the associated pharmacokinetic and clinical research.  Sustained release formulations of pharmaceutical ingredients that are otherwise short-acting (such as cannabinoids) have more convenient dosage schedules, a longer duration of action and tend to be much more accepted by patients and healthcare professionals.   Emblem expects that the introduction of easily titratable, sustained release formulations of cannabinoids will materially increase the market for cannabinoid-based medications, particularly for treatment of conditions such as chronic neuropathic pain.”  

Jeff Renwick, Canntab CEO said:  “We’re excited about the collaboration between us and Emblem.  It is a testament to the medicinal delivery technology developed by our team at Canntab. It also allows us to bring to the Canadian market a significant advancement in Cannabis based medicine. Canntab’s patent-pending extended release formulation for the first time lets doctors establish the appropriate dosage for their patients and will make taking medicinal cannabis easier for patients, which should translate into higher patient compliance, making for more effective treatment. The ongoing relationship with Emblem allows for further development of our unique platforms, advancing our mission to put the “medical” into medicinal cannabis.”

Gordon Fox, CEO of Emblem said: “We are very excited about our relationship with Canntab. We expect the Sustained Release Product to have a major impact on the Canadian medical cannabis market.  We are also looking forward to further collaborations with Canntab to bring other ground-breaking cannabis based advanced dosage forms to the market.”

About Emblem

Emblem is licensed under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) to cultivate and sell medical marihuana. Emblem carries out its principal activities producing marihuana from its facilities in Paris, Ontario pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations.

About Canntab

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab's mission is to put the "Medical" into medicinal cannabis!

For further information contact:

Ali Mahdavi

Emblem Corp.

(416) 962-3300

alimahdavi@emblemcorp.com

 

Ethan Karayannopoulos

647-748-9696

ethank@emblemcorp.com

   

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as "forward-looking statements") within the meaning of applicable Canadian securities laws. All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "anticipate", "achieve", "could", "believe", "plan", "intend", "objective", "continuous", "ongoing", "estimate", "outlook", "expect", "may", "will", "project", "should" or similar words, including negatives thereof, suggesting future outcomes.

In particular, this news release contains forward-looking statements relating to, among other things: (i) the arrangement and Agreement with Canntab; (ii) the benefits of the relationship with Canntab; (iii) potential sales of oil and the value thereof; (v) the ability of the Company to produce high quality dried flower; (vi) the intention to grow the business, operations and potential activities of the Company; (vii) the benefits associated with cannabinoids for the treatment of illness and disease; and (viii) receipt of approval from Health Canada to complete such activities.

Management of the Company believes the expectations reflected in such forward-looking statements are reasonable as of the date hereof but no assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon. Various material factors and assumptions are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements. Those material factors and assumptions are based on information currently available to the Company, including data from publicly available governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which Emblem believes to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. While Emblem is not aware of any misstatement regarding any industry or government data presented herein, the medical marijuana industry involves risks and uncertainties and is subject to change based on various factors.

Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks identified in the Company's filing statement dated November 30, 2016 and in the Company's short form prospectus dated March 16, 2017 both of which have been filed with the Canadian Securities Administrators and available on www.sedar.com. Any forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.

This news release contains future-oriented financial information and financial outlook information (collectively, "FOFI") about Emblem's prospective results of operations,  sales, revenues, funds flow, and components thereof, all of which are subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraphs. FOFI contained in this news release was made as of the date of this document and was provided for the purpose of providing further information about the Company's future business operations. The Company disclaims any intention or obligation to update or revise any FOFI contained in this news release, whether as a result of new information, future events or otherwise, unless required pursuant to applicable law. Readers are cautioned that the FOFI contained in this news release should not be used for purposes other than for which it is disclosed herein.

Rate this blog entry:
0

COSTA MESA, CA--(Marketwired - Mar 22, 2017) - NEMUS Bioscience, Inc. (OTCQB : NMUS ) and the company's discovery and research partner, the University of Mississippi (UM), today announced that bactericidal synergy was achieved against multiple species of methicillin-resistant Staphylococcus aureus (MRSA) utilizing a proprietary cannabinoid-based therapeutic platform. MRSA species tested included community acquired- (CA-MRSA), healthcare-acquired- (HA-MRSA), and mupirocin-resistant (MR-MRSA) strains of MRSA. 

In vitro studies demonstrated that when using unique strategic cannabinoid-based cocktails, fractional-inhibitory concentration (FIC) levels demonstrating synergy between mixtures of individual cannabinoid-based components ranged from 0.06 to 0.28. FIC findings below 0.5 indicate significant killing potential of the mixture.

"This work highlights the importance of Nemus' relationship with the University which has significant experience and intellectual capital related to cannabinoid chemistry and physiology, dating back to 1968," stated Brian Murphy, M.D., C.E.O. and Chief Medical Officer of Nemus. "These unique botanically derived components establish an anti-infective platform which could potentially be expanded into other types of bacteria, as well as viruses, and fungi."

Dr. Mahmoud ElSohly, professor at the National Center for Natural Products Research (NCNPR) at the University of Mississippi commented: "The University, in conjunction with Nemus, is looking to expand the anti-infective capabilities of this series of compounds. Historically, many types of anti-infective compounds are derived from plants so to have a series of cannabinoid-related compounds exhibit activity against this dangerous pathogen is in keeping with prior efforts of drug development. I believe that these compounds, in addition to the bacterial killing capability, could also offer benefits associated with anti-inflammatory and anti-fibrotic properties that could enhance healing, especially against an organism associated with skin and soft tissue infections."

"This anti-infective platform will constitute the NB3000 series of Nemus molecules and formulations. Recently, the World Health Organization (WHO) placed MRSA on their list as one of the top six organisms that pose a global public health threat. While there are a number of compounds in the development pipeline against MRSA, we believe that this family of drug candidates could possess an excellent safety profile in addition to efficacy in neutralizing this bacterium," stated Dr. Murphy. "Nemus will work with Dr. Elsohly, the University lead researcher on this project, to have this data submitted to a future scientific meeting and anticipates performing further testing against a variety of other bacterial species. Commercially, the company looks to actively pursue partnering opportunities for these candidate molecules."

FORWARD LOOKING STATEMENT

This press release contains forward-looking statements, including statements about the studies relating to and the potential benefits of the NB3000 series of drug candidates as well as the timing of our near term, intermediate term and long term goals. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "expects," "plans," "believes," "can," "could," "challenge," "predictable," "will," or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of NEMUS's most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, NEMUS disclaims any intent or obligation to update these forward-looking statements.

Rate this blog entry:
0
THE GREEN ORGANIC DUTCHMAN HOLDINGS LTD. PROVIDES SHAREHOLDER UPDATE AND ANNOUNCES $10 MILLION NON-BROKERED FINANCING

Dear Shareholders,
 
It is with great pleasure that I address you today as shareholders of our company, The Green Organic Dutchman Holdings Ltd. (“TGOD”).  Our Company has recently made major developments that I would like to report on. Additionally, I would like to announce a new financing.
 
Firstly, I would like to thank all of you who participated in our last financing, which I’m pleased to report was oversubscribed by 300%, allowing us to close on $13,200,000 with over 1,300 new shareholders.
 
Please always remember that we are a shareholder driven company, managed and directed by our shareholders.
 
UPDATE HIGHLIGHTS

  • The company successfully completed a heavily over-subscribed $13,200,000 initial financing
  • TGOD has secured an additional and contiguous 75-acre property bringing the incumbent land package to 100 acres,
  • The company has added significantly to both the corporate, operational and project management teams
  • Engineering and design for Phase 1 Expansion of 145,000 sq. ft. commenced in January. This expansion will increase the current annual productive capacity from 1,000KG’s to over 14,000KG’s.
  • Engaged Larssen Greenhouse Engineering, who specialises in the technical design and building of the most modern and sophisticated hybrid-greenhouses in the industry
  • Stratigic Partnership formed with Eaton, one of the worlds larget power management and energy optimization companies
  • Stratigic Partnership formed with Ledcor, one of Canadas largest construction management companies
  • TGOD announces it last planned financing prior to IPO
     

PROPERTY ACQUISITION
The Company secured 75-acres of contiguous land, directly adjoining the currently ACMPR licensed production facility. This additional land sets TGOD apart from much of its peers, allowing for large-scale and accelerated expansion plans.
 
PHASE 1 EXPANSION
Engineering and design for our Phase 1 expansion are well underway, and management anticipates construction to begin late in Q2, 2017. The Company has expedited its original plan and increased its size and scope, we will be executing on Phase 1, two-part expansion:
Hybrid Expansion:

  • A 125,000 sq. ft. of state-of-the-art, automated, hybrid facility
  • Additional annual capacity of ~11,000KG’s
  • Anticipated Q2 2018 initial harvest

Enclosed Expansion:

  • A 20,000 sq. ft. State of the art indoor facility
  • Additional annual capacity of ~2,000KG’s
  • Anticipated Q1 2018 initial harvest

Following the completion of the Phase 1 expansion, TGOD’s production capacity is expected to be ~14,000KG’s annually. The Company has built a team of highly experienced power, energy optimization and construction professionals to ensure this expansion is delivered not only on-time and on-budget but also completed to the highest possible standards, potentially setting a new standard for our industry.
 
OPERATIONAL MANAGEMENT TEAM ADDITIONS (full bios can be found in presentation)
Amer Cheema, M.Sc. (Hons.): Agriculture and a PhD Candidate in Post-Harvest Biology

  • Award winning head grower with +20 years experience in production & management of high-tech commercial greenhouses

 
Lola Millerman, B.Sc. in Biology from UBC

  • Senior Microbiologis and Labratory Supervisor with Nestle Canada

 
Brandan Leroux, M. Sc. Candidate: Environmental & Life Science, Trent University

  • Developed and implemented a research thesis in plant genetics with emphasis on environmental resource allocations specifically related to vegetative and sexual propagation

 
Chad Rigby, BSc in Environmental Biology from the University of Guelph, minor in Plant Sciences and Plant Biochemistry

  • Previously worked with another licesed producer as production assistant

 
CORPORATE MANAGEMENT TEAM ADDITIONS: (full bios can be found in presentation)
Jim Shone, MBA Queens, CFA

  • 20 years in the Canadian financial services industry, focused on small to medium sized enterprises. 12 years commercial banking experience (BDC for 7 years and factoring company for 4 ½ years)

Stevan Perry

  • 20+ years as senior energy services and major projects business development executive. Successfully developed and delivered on business models and project plans for fortune 100 companies such as Honeywell and Eaton.

Matt Schmidt, MBA Laurier University

  • Previously Vice President, Investment Banking at Echelon Wealth Partners - responsible for the firm’s initiation into the Canadian Cannabis sector

Danny Brody

  • 10+ years’ experience in finance and holds a Chartered Investment Manager (CIM) designation from the Canadian Securities Institute (CSI).  Previously Director of IR at Emblem Corp.

ADVISORS ADDITIONS: (full bios can be found in presentation)
Brian Ast, MBA, CFA, P.Eng

  • +20 years experience in project bid managemnt, contract and cost control for both the public and private sector. Curreently Director, Public & Private Partnerships with Honewell Building Solutions 

Harold Ruckpaul

  • 31 years of technical, operational and sales management experience with developing and implementing power systems solutions to primary mar­ket segments on a global scale.

Justin Fraser

  • 20+ years’ experience in team building, including the ability to select and implement strategic relationships for optimal business performance.  Currently Chairman & CEO of the Trades Labour Group.

We hope that you can appreciate the amount of work that has been accomplished in such a short period of time (just over 60 days), and we are not going to slow down, but rather pick-up the pace now that we have rounded out our operational, management and project construction teams. To keep you informed of our developments on a regular basis Danny Brody, VP IR will be sending out a monthly update and our IR department always welcomes your calls.

It is our belief that the foundation of this company is our shareholders and this is your company. As we the managing shareholders are hard at work we would like to call on all the other shareholders from time to time to help grow OUR business. This is one of those times, it is imperative to our business plan that we brand the TGOD name, create awareness of our upcoming product offerings from a grass roots level (all of you) and increase the number of shareholders. So, if you think you know someone that would like to learn about TGOD please take a moment and send a copy of our presentation to those interested parties.

This is the best way to grow any business and remember this is your Company.

In closing, we would like to announce the details of a proposed non-brokered equity financing to raise a minimum of $10,000,000.

The Green Organic Dutchman Holdings Ltd. (“Company”) is pleased to announce that it is conducting a best efforts equity financing to raise aggregate gross proceeds of $10,000,000 (the “Offering”) through the issuance of common share units (the "Units") at a price of $1.15 per Unit.  Each Unit will consist of one common share of the Company (a "Common Share") and one common share purchase warrant of the Company (a "Warrant"). Each Warrant is exercisable into one Common Share (the "Warrant Share") at the exercise price of $2.15 per share for a period of 24 months from the closing date (“Closing Date”) of the Offering.  It is intended that the Warrants will be transferable and will be subject to acceleration in the event that the volume weighted average price of the Common Shares is equal to or greater than $2.80 over a period of ten consecutive days. The Common Shares and Warrants will be subject to a six-month contractual escrow period from the date the Company’s common shares (or derivative thereof) are listed on an exchange (“Listing Date”). The Warrant Shares will be subject to a twelve-month contractual escrow period from the Closing Date.
 
"This is a unique retail shareholder driven financing, that allows as many potential patients to participate as an investor, in the upside of our Company," states Rob Anderson, CEO of TGOD.
 
Please note that if you have an interest in the financing contact our IR department.
To view a copy of the Company’s full corporate presentation please visit:

http://greenorganicdutchman.com/dl/TGOD.pdf
 
CONTACT INFORMATION :
Brett Allan
Email:
ballan@tgod.ca
Phone: 905-304-4201
www.tgod.ca
 
ABOUT GREEN ORGANIC DUTCHMAN
The Green Organic Dutchman Ltd. Produces Farm Grown, Pharma Grade Organic Cannabis. The Company grows high quality, organically grown medical cannabis in small batches using craft growing, all natural principles.  The Green Organic Dutchman Ltd. is licensed under the access to cannabis for medical purposes regulations (ACMPR) to cultivate medical marijuana, and carries out its principal activities producing marijuana from its facilities in Ancaster, Ont., pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations.
This update contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors -- including the availability of funds, the results of financing efforts and the parties' due diligence reviews, and general market conditions -- that could cause actual results to differ materially from the Company's expectations. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements

Rate this blog entry:
Recent comment in this post - Show all comments
  • Donald Baker
    Donald Baker says #
    I am interested in doing some retirement investment with growers cannabis etc. Are you an investment person to discuss investing i

Select Your Language

enzh-CNnlfrdehies